Mkts

Krystal Biotech, Inc.

NASDAQ: KRYS
$300.88+0.63 (+0.21%)
As of Nov 6, 4:00 PM ET

Key statistics

Day range
297.52305.60
52-week range
192.52382.54
Today
Open298.31
Previous close300.88
Volume—
Valuation
Market cap8.92B
P/E ratio39.60×
EPS (TTM)7.36
Income & risk
Dividend / yield—
Beta0.74
Avg volume360.2K
Discussion

KRYS News

Stories mentioning KRYS from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue116,357107,10597,80096,04288,18391,14083,84170,284
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development15,33114,79414,58514,41014,25613,52813,51215,583
Sales General & Admin41,01441,35637,57835,16032,64731,26928,67327,626
Total Operating Expenses62,66862,74356,42656,73551,93149,74661,36961,718
Operating Income (Loss)53,68944,36241,37439,30736,25241,39422,4728,566
Interest Income
Interest Expense
Other Expense
Pretax Income61,44251,13247,96746,77543,59748,61029,76916,045
Tax Provision5,510(268.00)(31,398)8,4427,8643,1312,589477.00
Net Income (Loss)55,93251,40079,36538,33335,73345,47927,18015,568
Earnings Per Share (Basic)1.911.782.741.331.241.590.950.54
Earnings Per Share (Diluted)1.831.722.661.291.201.530.910.53
Weighted Average Shares Outstanding (Basic)29,28828,94428,95328,91028,81528,59228,71628,598
Weighted Average Shares Outstanding (Diluted)30,50729,95129,83329,74929,87129,74029,90229,637

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About KRYS

Krystal Biotech, Inc. (NASDAQ: KRYS) is a stock listed on the Nasdaq Stock Market under the ticker symbol KRYS. It last traded at $300.88 (Nov 6, 2026, 4:00 PM ET), up 0.2% on the day. That gives Krystal Biotech a market capitalisation of $8.9B and a price-to-earnings ratio of 39.6.

Over the past 52 weeks KRYS has traded between $192.52 and $382.54.

Revenue for the quarter ended Mar 31, 2026 was $116.4M; net income $55.9M. Revenue was up 31.9% from $88.2M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$116.4M$55.9M48.1%
Dec 31, 2025$107.1M$51.4M48.0%
Sep 30, 2025$97.8M$79.4M81.2%
Jun 30, 2025$96.0M$38.3M39.9%

From Krystal Biotech’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…